{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:19:06Z","timestamp":1773281946517,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1124\/jpet.103.061705","type":"journal-article","created":{"date-parts":[[2004,4,22]],"date-time":"2004-04-22T00:29:43Z","timestamp":1082593783000},"page":"745-757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":116,"title":["Prostaglandin Ethanolamides (Prostamides): In Vitro Pharmacology and Metabolism"],"prefix":"10.1016","volume":"309","author":[{"given":"I.","family":"Matias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"De Petrocellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Bisogno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ligresti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Fezza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.H.-P.","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.E.","family":"Protzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.L.","family":"Nieves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.M.","family":"Kedzie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.M.","family":"Burk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Di Marzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.F.","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.103.061705_bib1","doi-asserted-by":"crossref","unstructured":"Abelson MB, Mroz M, Rosner SA, Dirks MS, and Hirabayashi D (2003) Multicenter, open-label evaluation of hyperemia associated with use of bimatoprost in adults with open-angle glaucoma or ocular hypertension. Adv Ther 20: 1-13.","DOI":"10.1007\/BF02850114"},{"key":"10.1124\/jpet.103.061705_bib2","doi-asserted-by":"crossref","unstructured":"Berglund BA, Boring DL, and Howlett AC (1999) Investigation of structural analogs of prostaglandin amides for binding to and activation of CB1 and CB2 cannabinoid receptors in rat brain and human tonsils. Adv Exp Med Biol 469: 527-533.","DOI":"10.1007\/978-1-4615-4793-8_77"},{"key":"10.1124\/jpet.103.061705_bib3","doi-asserted-by":"crossref","unstructured":"Bisogno T, De Petrocellis L, and Di Marzo V (2002) Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr Pharm Des 8: 533-547.","DOI":"10.2174\/1381612023395655"},{"key":"10.1124\/jpet.103.061705_bib4","doi-asserted-by":"crossref","unstructured":"Bisogno T, Maurelli S, Melck D, De Petrocellis L, and Di Marzo V (1997) Biosynthesis, uptake and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem 272: 3315-3323.","DOI":"10.1074\/jbc.272.6.3315"},{"key":"10.1124\/jpet.103.061705_bib5","doi-asserted-by":"crossref","unstructured":"Burstein SH, Huang SM, Petros TJ, Rossetti RG, Walker JM, and Zurier RB (2002) Regulation of anandamide tissue levels by N-arachidonylglycine. Biochem Pharmacol 64: 1147-1150.","DOI":"10.1016\/S0006-2952(02)01301-1"},{"key":"10.1124\/jpet.103.061705_bib6","doi-asserted-by":"crossref","unstructured":"Chen J, Champa-Rodriguez ML, and Woodward DF (1995) Identification of a prostanoid FP receptor population producing endothelium-dependent vasorelaxation in the rabbit jugular vein. Br J Pharmacol 116: 3035-3041.","DOI":"10.1111\/j.1476-5381.1995.tb15960.x"},{"key":"10.1124\/jpet.103.061705_bib7","doi-asserted-by":"crossref","unstructured":"Chen J and Woodward DF (2002) Prostanoid FP receptor-mediated, endothelium-dependent vasodilatation and the ocular surface hyperemic response to PGF2\u03b1 and related compounds, in Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, 5 (Honn, KV, Marnett LJ, Nigam S, Serhan CN, and Dennis EA eds) pp 331-336, Kluwer Academic\/Plenum Publishers, New York.","DOI":"10.1007\/978-1-4615-0193-0_51"},{"key":"10.1124\/jpet.103.061705_bib8","doi-asserted-by":"crossref","unstructured":"Coleman RA, Humphrey PPA, Kennedy I, and Lumley P (1984) Prostanoid receptors: the development of a working classification. Trends Pharmacol Sci 5: 303-306.","DOI":"10.1016\/0165-6147(84)90452-8"},{"key":"10.1124\/jpet.103.061705_bib9","doi-asserted-by":"crossref","unstructured":"Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, and Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fattyacid amides. Nature (Lond) 384: 83-87.","DOI":"10.1038\/384083a0"},{"key":"10.1124\/jpet.103.061705_bib10","doi-asserted-by":"crossref","unstructured":"Cravatt BF and Lichtman AH (2002) The enzymatic inactivation of the fatty acid amide class of signaling lipids. Chem Phys Lipids 121: 135-148.","DOI":"10.1016\/S0009-3084(02)00147-0"},{"key":"10.1124\/jpet.103.061705_bib11","doi-asserted-by":"crossref","unstructured":"De Petrocellis L, Bisogno T, Maccarrone M, Davis JB, Finazzi-Agro A, and Di Marzo V (2001) The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem 276: 12856-12863.","DOI":"10.1074\/jbc.M008555200"},{"key":"10.1124\/jpet.103.061705_bib12","doi-asserted-by":"crossref","unstructured":"Di Marzo V (1998) `Endocannabinoids\u2019 and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim Biophys Acta 1392: 153-175.","DOI":"10.1016\/S0005-2760(98)00042-3"},{"key":"10.1124\/jpet.103.061705_bib13","doi-asserted-by":"crossref","unstructured":"Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, and Bisogno T (2002) Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids 66: 377-391.","DOI":"10.1054\/plef.2001.0349"},{"key":"10.1124\/jpet.103.061705_bib14","doi-asserted-by":"crossref","unstructured":"Fowler CJ and Jacobsson SO (2002) Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide-targets for drug development? Prostaglandins Leukot Essent Fatty Acids 66: 193-200.","DOI":"10.1054\/plef.2001.0357"},{"key":"10.1124\/jpet.103.061705_bib15","doi-asserted-by":"crossref","unstructured":"Giles H, Leff P, Bolofo ML, Kelly MG, and Robertson AD (1989) The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist. Br J Pharmacol 96: 291-300.","DOI":"10.1111\/j.1476-5381.1989.tb11816.x"},{"key":"10.1124\/jpet.103.061705_bib16","doi-asserted-by":"crossref","unstructured":"Griffin BW, Klimko P, Crider JY, and Sharif NA (1999) Al-8810: a novel prostaglandin F2\u03b1 analog with selective antagonist effects at the prostaglandin F2\u03b1 (FP) receptor. J Pharmacol Exp Ther 290: 1278-1284.","DOI":"10.1016\/S0022-3565(24)35032-3"},{"key":"10.1124\/jpet.103.061705_bib17","doi-asserted-by":"crossref","unstructured":"Jung J, Hwang SW, Kwak J, Lee SY, Kang CJ, Kim WB, Kim D, and Oh U (1999) Capsaicin binds to the intracellular domain of the capsaicin-activated ion channel. J Neurosci 19: 529-538.","DOI":"10.1523\/JNEUROSCI.19-02-00529.1999"},{"key":"10.1124\/jpet.103.061705_bib18","doi-asserted-by":"crossref","unstructured":"Kozak KR, Crews BC, Morrow JD, Wang LH, Ma YH, Weinander R, Jakobsson PJ, and Marnett LJ (2002) Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277: 44877-44885.","DOI":"10.1074\/jbc.M206788200"},{"key":"10.1124\/jpet.103.061705_bib19","doi-asserted-by":"crossref","unstructured":"Kozak KR, Crews BC, Ray JL, Tai HH, Morrow JD, and Marnett LJ (2001) Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. J Biol Chem 276: 36993-36998.","DOI":"10.1074\/jbc.M105854200"},{"key":"10.1124\/jpet.103.061705_bib20","doi-asserted-by":"crossref","unstructured":"Kozak KR and Marnett LJ (2002) Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 66: 211-220.","DOI":"10.1054\/plef.2001.0359"},{"key":"10.1124\/jpet.103.061705_bib21","doi-asserted-by":"crossref","unstructured":"Lawrence RA and Jones RL (1992) Investigation of the prostaglandin E (EP-) receptor subtype mediating relaxation of the rabbit jugular vein. Br J Pharmacol 105: 817-824.","DOI":"10.1111\/j.1476-5381.1992.tb09063.x"},{"key":"10.1124\/jpet.103.061705_bib22","doi-asserted-by":"crossref","unstructured":"Maccarrone M, Attina M, Bari M, Cartoni A, Ledent C, and Finazzi-Agro A (2001) Anandamide degradation and N-acylethanolamines level in wild-type and CB1 cannabinoid receptor knockout mice of different ages. J Neurochem 78: 339-348.","DOI":"10.1046\/j.1471-4159.2001.00413.x"},{"key":"10.1124\/jpet.103.061705_bib23","doi-asserted-by":"crossref","unstructured":"Maddox YT, Ramwell PW, Shiner CS, and Corey EJ (1978) Amide and 1-Amino derivatives of prostaglandins as prostaglandin antagonists. Nature (Lond) 273: 549-552.","DOI":"10.1038\/273549a0"},{"key":"10.1124\/jpet.103.061705_bib24","doi-asserted-by":"crossref","unstructured":"Maurelli S, Bisogno T, De Petrocellis L, Di Luccia A, Marino G, and Di Marzo V (1995) Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma `anandamide amidohydrolase\u2019. FEBS Lett 377: 82-86.","DOI":"10.1016\/0014-5793(95)01311-3"},{"key":"10.1124\/jpet.103.061705_bib25","doi-asserted-by":"crossref","unstructured":"Maxey KM, Johnson JL, and Labrecque J (2002) The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol 47: S34-S40.","DOI":"10.1016\/S0039-6257(02)00323-5"},{"key":"10.1124\/jpet.103.061705_bib26","doi-asserted-by":"crossref","unstructured":"Milne SA, Armstrong RA, and Woodward DF (1995) Comparison of the EP receptor subtypes mediating relaxation of the rabbit jugular and pig saphenous veins. Prostaglandins 49: 225-237.","DOI":"10.1016\/0090-6980(95)00018-6"},{"key":"10.1124\/jpet.103.061705_bib27","unstructured":"Nials AT, Coleman RA, Hartley D, and Sheldrick RLG (1991) AH13205 - a novel selective prostanoid EP2 agonist. Br J Pharmacol 102: 24P."},{"key":"10.1124\/jpet.103.061705_bib28","doi-asserted-by":"crossref","unstructured":"Regan JW, Bailey TJ, Pierce K, Zheng D, Donello J, Kedzie KM, Woodward DF, Fairbairn CE, and Gil DW (1994) Molecular cloning and expression of human EP3 receptors: evidence of 3 variants with differing carboxyl termini. Br J Pharmacol 112: 377-385.","DOI":"10.1111\/j.1476-5381.1994.tb13082.x"},{"key":"10.1124\/jpet.103.061705_bib29","doi-asserted-by":"crossref","unstructured":"Reggio PH (2002) Endocannabinoid structure-activity relationships for interaction at the cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids 66: 143-160.","DOI":"10.1054\/plef.2001.0343"},{"key":"10.1124\/jpet.103.061705_bib30","doi-asserted-by":"crossref","unstructured":"Resul B, Stjernschantz J, Selen G, and Bito L (1997) Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids. Surv Ophthalmol 41 (Suppl 2): S47-S52.","DOI":"10.1016\/S0039-6257(97)80007-0"},{"key":"10.1124\/jpet.103.061705_bib31","doi-asserted-by":"crossref","unstructured":"Ross RA, Craib SJ, Stevenson LA, Pertwee RG, Henderson A, Toole J, and Ellington HC (2002) Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide. J Pharmacol Exp Ther 301: 900-907.","DOI":"10.1124\/jpet.301.3.900"},{"key":"10.1124\/jpet.103.061705_bib32","doi-asserted-by":"crossref","unstructured":"Sharif NA, Williams GW, and Kelly CR (2001) Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur J Pharmacol 432: 211-213.","DOI":"10.1016\/S0014-2999(01)01486-8"},{"key":"10.1124\/jpet.103.061705_bib33","doi-asserted-by":"crossref","unstructured":"Ueda N and Yamamoto S (2000) Anandamide amidohydrolase (fatty acid amide hydrolase). Prostaglandins Other Lipid Mediat 61: 19-28.","DOI":"10.1016\/S0090-6980(00)00052-6"},{"key":"10.1124\/jpet.103.061705_bib34","doi-asserted-by":"crossref","unstructured":"van der Stelt M, Van Kuik JA, Bari M, Van Zadelhoff G, Leeflang BR, Veldink GA, Finazzi-Agro A, Vliegenthart JF, and Maccarrone M (2002) Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter and fatty acid amide hydrolase. J Med Chem 45: 3709-3720.","DOI":"10.1021\/jm020818q"},{"key":"10.1124\/jpet.103.061705_bib35","doi-asserted-by":"crossref","unstructured":"Woodward DF, Krauss AH, Chen J, Gil DW, Kedzie KM, Protzman CE, Shi L, Chen R, Krauss HA, Bogardus A, et al. (2000) Replacement of the carboxylic acid group of prostaglandin F2\u03b1 with a hydroxyl or methoxy substituent provides biologically unique compounds. Br J Pharmacol 130: 1933-1943.","DOI":"10.1038\/sj.bjp.0703462"},{"key":"10.1124\/jpet.103.061705_bib36","doi-asserted-by":"crossref","unstructured":"Woodward DF, Krauss AH, Chen J, Lai RK, Spada CS, Burk RM, Andrews SW, Shi L, Liang Y, Kedzie KM, et al. (2001) The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol 45: S337-S345.","DOI":"10.1016\/S0039-6257(01)00224-7"},{"key":"10.1124\/jpet.103.061705_bib37","doi-asserted-by":"crossref","unstructured":"Woodward DF, Krauss AH, Chen J, Liang Y, Li C, Protzman CE, Bogardus A, Chen R, Kedzie KM, Krauss HA, et al. (2003) Pharmacological characterization of a novel antiglaucoma agent, bimatoprost (AGN 192024). J Pharmacol Exp Ther 305: 772-785.","DOI":"10.1124\/jpet.102.047837"},{"key":"10.1124\/jpet.103.061705_bib38","doi-asserted-by":"crossref","unstructured":"Yu M, Ives D, and Ramesha CS (1997) Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem 272: 21181-21186.","DOI":"10.1074\/jbc.272.34.21181"},{"key":"10.1124\/jpet.103.061705_bib39","doi-asserted-by":"crossref","unstructured":"Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, and Hogestatt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature (Lond) 400: 452-457.","DOI":"10.1038\/22761"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524313370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524313370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.103.061705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:52:41Z","timestamp":1739998361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524313370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0022356524313370"],"URL":"https:\/\/doi.org\/10.1124\/jpet.103.061705","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostaglandin Ethanolamides (Prostamides): In Vitro Pharmacology and Metabolism","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.103.061705","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2004 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}